Encorium Q3 net loss widens
Net revenue for the third quarter of 2008 was $7.4 million, an increase of 3.5%, compared to $7.2 million for the third quarter of 2007. The increase in

Net revenue for the third quarter of 2008 was $7.4 million, an increase of 3.5%, compared to $7.2 million for the third quarter of 2007. The increase in

The FDA also approved PLC’s request to expand their investigation from the 246 patients conditionally approved earlier this year to 406 patients and eliminate the requirement for an

Together with the new SITUS BW 28D left ventricle pacing lead and lead delivery system, Paradym CRT forms a complete new CRT system for heart failure patients, the

The clinical study will evaluate the sensitivity and specificity of X-ray mammography (XRM) and automated breast ultrasound system (ABUS) together, as compared to XRM alone, as a breast

Under terms of the agreement, upon the closing of the transaction the companies will become the sole members of a limited liability company (LLC) whose sole purpose would

If this test-marketing is agreed to be successful by both parties Tagerr will then be made ReGen’s exclusive distributor for Poland subject to Tagerr being able to secure

Biogen Idec has an option to license the Amorfix technology for amyotrophic lateral sclerosis (ALS) under already defined terms and would be responsible for completing preclinical and clinical

Oncology Services India (OSI) will offer a complete clinical service range from Phase I (first-in-men) to Phase IV (PMS) trials. The company said that it plans to offer

From a functional perspective, the instruments in the Ortoviva distractor solution hold and separate the two vertebrae adjacent to a damaged disc. This ability to mechanically control position

Violeta Rajkovska, AnaSpec’s director of sales and marketing, said: “AnaSpec is pleased to partner with Biogenuix Medsystems to expand the availability of our integrated proteomics solutions to researchers